Subtype
Malignant Intracranial Neoplasm
CI-CAN-00003169Explore in graph →
192 active trials28 evidence items
- NCIt
- C5114
Loading cancer entity…
Subtype
CI-CAN-00003169Explore in graph →
Clinical trials
637 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (100)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT02861898 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 33 | Northwell HealthOTHER | 1 | Jun 1, 2026 |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06048094 | 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery(FACILITATE) | recruiting | Phase 1 | 46 | Baptist Health South FloridaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07003139 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors | recruiting | Phase 1 / Phase 2 | 10 | China Medical University HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05293197 | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients(SONOKID) | recruiting | Phase 1 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07569042 | A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 15 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03465618 | A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors | active not recruiting | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06012695 | NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 79 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04689048 | Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery | recruiting | Phase 1 | 20 | Baptist Health South FloridaOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02852655 | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | active not recruiting | Phase 1 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04510051 | CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children | recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07438860 | Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG | not yet recruiting | Phase 1 | 12 | Tiffany HodgesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06342908 | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | active not recruiting | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05762419 | FUS Etoposide for DMG | recruiting | Phase 1 | 10 | Columbia UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07331064 | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor(GABRIEL) | not yet recruiting | Phase 1 | 15 | Sarah RumlerOTHER | 0 | Jan 9, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | active not recruiting | Phase 1 | 72 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | terminated | Phase 1 / Phase 2 | 21 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)(BRAVO) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT07179328 | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | recruiting | Phase 1 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07158710 | Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 159 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT01478178 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 55 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05169944 | Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors(PNOC025) | completed | Phase 1 | 13 | University of California, San FranciscoOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06896110 | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | enrolling by invitation | Phase 1 | 34 | Andrew P. GrovesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2026source: clinicaltrials